First-Time KEYTRUDA Monotherapy Data in Clear Cell RCC
to be Presented at 2018 ASCO Annual Meeting
KENILWORTH, N.J., June 3, 2018 – Merck (NYSE:
MRK), known as MSD outside the United States and Canada, today announced
interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating
KEYTRUDA, Merck’s anti-PD-1 therapy, as first-line treatment for advanced
clear cell renal cell carcinoma (RCC). Interim data showed an overall response
rate (ORR) of 38.2 percent (95% CI, 29.1-47.9) in patients who received
KEYTRUDA monotherapy as first-line therapy, the primary endpoint of the study.
In a pre-specified, exploratory sub-group analysis based on PD-L1 status, ORR
was 50.0 percent (95% CI, 34.9-65.1) in patients whose tumors expressed PD-L1
(CPS ≥1). In a pre-specified exploratory sub-group analysis based on the
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk
model, ORR was 42.0 percent (95% CI, 30.2-54.5) in patients with
intermediate/poor prognostic risk. This is the first presentation of Phase 2
data for an anti-PD-1 monotherapy as first-line treatment for advanced clear
cell RCC. These results, as well as other study findings, are being presented
today in an oral session at the 2018 American Society of Clinical Oncology
(ASCO) Annual Meeting (Abstract #4500).
The attached news release crossed the wire today,
Sunday, June 3, 2018 at 9:00 a.m. ET.
0 comentários:
Postar um comentário